CH
Draguignan, France
CH
Draguignan, France

Time filter

Source Type

Sky as the Limit, a new, revolutionary eCommerce and information based platform designed to bring all site visitors the tips, tricks, industry updates, and latest products in the ever expanding and ever elusive Drone Aircraft industry, this week officially opened its virtual doors to all individuals intent on being part of the drone revolution in the United States today. Borne from the passion of a longtime pilot to bring the benefits and transportation abilities of drones into the future, Sky as the Limit is set to sell its listed drones to customers throughout the world. “Drones are the latest thing in air travel – and their potential for consumer revolution is enormous,” said Frank Nesbitt, Founder and Owner of Sky as the Limit. “These little robotic elements are going to change how we interact, how we receive packages, how we send packages, how we deliver information, and so much more. This platform is here to be part of this change.” Sky as the Limit’s inventory updates daily to bring new drone models and versions to the forefront of the platform. Products currently available for purchase include X600 2.4GHz 4 CH 6 Axis Hexacopter With Headless Mode & Auto Return, X500 2.46 6 Axis 3D Roll FPV Quadcopter, X101 Quadcopter 2.4g 6-Axis RC Drone, and SymaX5C Explorers 4CH 2.4GHz 6 Axis Gyro RC Quadcopter +2.0MP HD Camera. “Now is the time to get ahead of the revolutionary change possible with the drone industry,” said Nesbitt. “This platform is here to aid in that quest. Spread the word on the opening of our store front, and head on over today to check out our drone inventory.”


News Article | April 20, 2017
Site: www.greencarcongress.com

A team at the Loker Hydrocarbon Research Institute and Department of Chemistry, University of Southern California, has demonstrated a novel hydrogen storage system based on the release of hydrogen from catalytic dehydrogenative coupling of methanol and 1,2-diamine. The hydrogen-generating step of this process can be termed as “amine reforming of methanol”—in analogy to traditional steam methane reforming, but without the concurrent production of CO (unlike steam reforming) or CO (by complete methanol dehydrogenation). A paper on the team’s work, which is part of their long-term development of aspects of the “Methanol Economy” (earlier post), is published in the Journal of the American Chemical Society. The products of the dehydrogenation reaction—N-formamide and N,N′- diformamide—are hydrogenated back to the free amine and methanol by a simple hydrogen pressure swing. Both H “loading” and “unloading” are performed in the presence of the same Ru-pincer catalysts. As a hydrogen carrier, liquid organic hydrogen carriers (LOHC) have gained significant attention recently as they are safe to store and transport, have high wt % H storage capacities and can offer fully reversible H loading and unloading. They can also enable a relatively easy transition by allowing the utilization of existing fuel infrastructures. Formic acid (HCO H), over the years, has been explored thoroughly as a potential LOHC, and highly efficient catalysts for both H loading and unloading have been designed by us and others. However, a maximum H storage of only 4.4 wt % is feasible in HCO H with the emission of stoichiometric amount of CO for each H . Methanol (CH OH) is a good alternative because of its 12.6 wt % H content, ease of handling and convenient production. Steam reforming of CH OH is generally the preferred method to obtain H and is performed at high temperatures (240−260 °C) and high pressures over heterogeneous catalysts. Recently, it was discovered that the use of homogeneous catalysts, mainly Ru13 and Fe14 pincer complexes, could also enable aqueous CH OH dehydrogenation at much lower temperatures (2 reduction to CH OH has also been reported using similar pincer catalysts. However, to the best of our knowledge, aqueous reforming of CH OH and the reverse reaction (CO hydrogenation to CH OH) in the presence of same homogeneous catalytic system has not yet been demonstrated. The authors said that their process has three main advantages over traditional methanol steam reforming in the context of sustainable H storage and transportation: The USC process is essentially a carbon-neutral cycle—the carbon is trapped in the form of formamide (or urea in the case of primary amine). In theory, the team said, a hydrogen storage capacity as high as 6.6 wt % is achievable. Dehydrogenative coupling and the subsequent amide hydrogenation proceed with good yields (90% and >95% respectively, with methanol and N,N′-dimethylethylenedi- amine as dehydrogenative coupling partners). The paper describing the method was the the last major paper co-authored by USC’s first Nobel laureate, the late George Olah. “The Methanol Economy” is a concept that the Olah-Prakash team first began refining in the mid-1990s, right after Olah was awarded a Nobel Prize in Chemistry in 1194 for his contributions to carbocations—the name that Olah himself coined for ions that have a positively charged carbon atom. According to Olah and Prakash, the goal of a methanol-based economy would be to develop renewable sources of energy, led by methanol, that could mitigate the problem of climate change caused by carbon emissions, as well as the US dependence on other countries for energy, particularly oil. Prakash, Olah and their team have been focused on finding a way to extract hydrogen fuel from methanol in ways that are not only carbon-neutral, but can even be carbon-positive. The research was supported by the USC Loker Hydrocarbon Research Institute.


News Article | May 2, 2017
Site: news.yahoo.com

Israeli F-35 fighter jets perform during an air show over the Israeli coastal city of Tel Aviv on May 02, 2017 to mark Independence Day (AFP Photo/JACK GUEZ) Tel Aviv (AFP) - Israel showed off its new F-35 stealth fighter jets recently delivered from the United States on Tuesday as part of an air show marking its annual Independence Day celebrations. Three of Israel's five stealth fighters took to the skies along the Mediterranean coast off Tel Aviv as thousands of people gathered at the waterfront to watch. They also flew over other cities including Jerusalem. The F-35s, made by US-based Lockheed Martin, were the highlight of the show, which marked 69 years of Israeli independence. The event also included aircraft such as the F-15 and F-16 jets, Sikorsky CH-53 Stallion helicopters, a KC-135 Stratotanker Boeing 707, and the Hawker-Beechcraft T-6 Texan II planes. Israel has received the initial five F-35s since December with the aim of allowing it to maintain its military superiority in the turbulent Middle East, particularly regarding its arch-foe Iran. It plans to purchase a total of 50 F-35s. Its first jets are to be operational this year. While other countries have ordered the planes, Israel -- which receives more than $3 billion a year in US defence aid -- says it will be the first outside the United States with an operational F-35 squadron. Israel is buying its first 33 F-35s at an average price of about $110 million (103.5 million euros) each -- and the price tag has been criticised both in Israel and elsewhere. The first two F-35s delivered to Israel in December landed around six hours late after being delayed by bad weather in Italy, believed to be fog. A Lockheed official said then the holdup was caused by Italian air safety regulations, rather than any limitation of the planes, but this did not stop jibes. "Here's hoping we only go to war on sunny days..." one Israeli joked on Twitter. Among its main features are advanced stealth capabilities to help pilots evade sophisticated missile systems. The single-pilot jets can carry an array of weapons and travel at a supersonic speed of Mach 1.6, or around 1,200 miles per hour (1,900 kilometres per hour). The pilot's ultra-high-tech helmet, at a cost of about $400,000 each, includes its own operating system, with data that appears on the visor and is also shared elsewhere. Thermal and night vision as well as 360-degree views are possible with cameras mounted on the plane. In February, Lockheed Martin and the Pentagon said the next batch of F-35s, the most expensive planes in history, will be produced at a reduced cost. They announced $728 million in savings after President Donald Trump publicly upbraided Lockheed over "out of control" costs, although most of the savings were already planned ahead of his involvement, during a months-long contract negotiation. For more news videos visit Yahoo View, available now on iOS and Android.


News Article | May 3, 2017
Site: www.nature.com

On page 84, Juliá-Hernández and co-workers1 report a remarkable feat of chemical selectivity: a process that converts isomeric mixtures of compounds known as alkenes into single fatty acids, by reacting them with the greenhouse gas carbon dioxide. The process not only overcomes a problem that has long hampered the chemical processing of petroleum-derived alkenes, but also might have many applications — fatty acids are crucial ingredients in products such as rubber, soaps and plastics, and it is estimated2 that they will have a global market value of US$20 billion by 2023. The past 100 years have witnessed remarkable discoveries that have greatly advanced the synthetic use of alkenes — simple hydrocarbons that contain carbon–carbon double bonds (C=C bonds). Reactions of C=C bonds have thus become central to the synthesis of products ranging from plastics to complex pharmaceutical agents, because they enable the ready conversion of cheap and abundant petroleum-derived alkenes to value-added products. But such alkenes are often mixtures of regioisomers, in which the C=C bond is located at different positions along a hydrocarbon backbone. Reactions of regioisomeric alkene mixtures frequently yield multiple products, which must be separated, and at great cost. Some chemical processes circumvent this problem, but reactions in which regioisomeric alkenes selectively generate single products remain rare3. The production of fatty acids also comes with selectivity problems. Most fatty acids are prepared on industrial scales by breaking down animal- and plant-derived lipids using water4. This allows fatty acids to be used as a renewable feedstock chemical (a raw material that can be used in bulk for industrial processes), but the compounds are mainly isolated as complex mixtures of fatty acids of varying chain lengths. Separation by fractional distillation and further chemical modification are subsequently required to generate the pure, non-natural fatty acids typically required for the production of fine chemicals, such as pharmaceutical ingredients or detergents. An alternative approach commonly adopted for making short-chain acids involves the reaction of simple alkenes with carbon monoxide (a cheap feedstock gas) and water. This process, known as hydrocarboxylation, can be promoted by metal catalysts. For example, the industrial production of propanoic acid (C H COOH) relies on the nickel-catalysed hydrocarboxylation of ethene (CH =CH ), another abundant, petroleum-derived feedstock gas5. Notably, the high natural abundance of nickel makes it an economical and sustainable alternative to commonly used precious-metal catalysts. But although hydrocarboxylation works well for pure, simple alkene substrates, regioisomeric alkene mixtures generate product mixtures that are difficult to separate. Juliá-Hernández and co-workers have developed a two-step process that converts isomeric alkenes and CO into single fatty acids (Fig. 1). The process begins by exposing mixtures of regioisomeric alkenes to hydrobromic acid, which adds a hydrogen and a bromine atom across the C=C bond in each isomer. In the second step, a catalyst — consisting of a nickel atom in complex with a large ligand molecule — inserts its nickel atom into the resulting carbon–bromine bond, forming an intermediate that contains a carbon–nickel (C–Ni) bond in the middle of a hydrocarbon chain. Interactions between the bulky nickel complex and neighbouring hydrocarbon groups destabilize this intermediate. Through a series of previously well-characterized organometallic processes, the nickel group subsequently 'walks' down the chain until it reaches a position that is free from these adverse interactions. The C–Ni bond then reacts with CO gas, a process known as carboxylation, forming a single fatty-acid product and regenerating the catalyst. Central to the success of this process is the chain-walking event. Compounds that contain C–Ni bonds often decompose through a pathway called β-hydride elimination, which forms an alkene and a compound that contains a nickel–hydrogen (Ni–H) bond. Importantly, this process is reversible, which means that the nickel and hydrogen atoms in the Ni–H bond can reattach to the alkene to form one of two possible isomeric nickel-containing compounds. One of these isomers is the same species that generated the alkene, but the other contains a C–Ni bond at the next carbon atom along the hydrocarbon chain — as though the nickel atom has taken a step along the chain. Juliá-Hernández et al. have fashioned this often deleterious side reaction into the directable chain-walking event described above. The chain-walking event is analogous to that observed with certain zirconium-containing reagents6, but Juliá-Hernández and co-workers' process is catalytic and uses a widely available, inexpensive nickel salt, which makes the process potentially economically viable for fine-chemical production. The authors also found that chain walking could be initiated directly from a wide range of alkyl bromides (the bromine-containing compounds formed as intermediates in the first step of the process), rather than from alkenes, to form diverse acids in good yields. These acids could be used as versatile intermediates for organic synthesis. Juliá-Hernández et al. also performed their reaction using alkyl bromides that contain carbonyl (C=O) groups, which can stabilize adjacent carbon–metal bonds. The authors observed that carboxylation occurred preferentially next to the stabilizing groups in reactions carried out at 42–50 °C, whereas reactions at lower temperatures (10–25 °C) favoured carboxylation at the terminal position of the hydrocarbon chain, with modest to excellent selectivities. This provides a simple method for selectively generating either one of two products from a single set of reactants, and will be a powerful tool for synthesizing variants of structurally complex compounds. The authors' catalytic method enables the selective synthesis of useful fatty acids from readily available building blocks. Although still at a preliminary stage, these reactions could potentially underpin a new approach to the industrial production of fatty acids. Moreover, if other chain-walking events can be designed that terminate in reactions with reagents other than CO , this would dramatically expand the portfolio of chemicals that can be made from alkenes. At present, a two-step process is needed to convert petroleum-derived alkenes into fatty acids. But if a one-step, nickel-catalysed carboxylation can be developed for alkenes (or even for alkanes, analogues of alkenes that contain only single carbon–carbon bonds, and for which the authors also show some exciting preliminary results), it would open up these abundant chemical feedstocks for use in research in synthetic chemistry.


Hydrogels are networks of cross-linked macromolecular chains that have a highly porous structure enabling them to become swollen with water. They are soft structures with often complex viscoelastic properties that can be fine-tuned by adapting their chemical components and their cross-linking density. In this manner, they can be adapted to sense and adjust to changes in their environment, such as temperature, pH, pressure, light, or even the presence of other chemicals. A well-known family of hydrogels based on poly(ethylene oxide) (PEO) copolymers were combined with a mechanically robust polymer known as Nafion. The properties of the novel polymer complexes were revealed by a host of techniques, including Small Angle X-ray Scattering (SAXS) at the Small Angle Scattering and Diffraction beamline (I22) at Diamond Light Source. The addition of Nafion was shown to dramatically improve the mechanical properties of the hydrogels, making them a promising candidate for a variety of applications such as drug-release systems and 3-D-bioprinting. One of the most fascinating applications of hydrogels is in the field of drug-release. Hydrogels can be ingeniously tuned to change their phase from an injectable liquid into a gel within the body, which gradually dissolves to slowly release an entrapped drug. The benefits of this are wide-reaching for patients and healthcare professionals alike. Typically, injectable hydrogels are based on PEO copolymers as they are well characterised and have a defined phase transition to a gel at body temperature. However, these hydrogels have weak mechanical properties and release drugs rapidly. To address the shortcomings of the current wave of injectables, a team of scientists from the University of Central Lancashire, combined them with a mechanically stable polymer known as Nafion. This polymer was discovered in the late 1960s and has a unique array of properties that have led to its use as a proton exchange membrane for fuel cells. Since its biocompatible and nontoxic nature has been recently revealed, Nafion has also been used for biomedical applications such as implant coatings and biosensors. The team prepared mixtures of Nafion with two different copolymers: E P E and B E (where E was OCH CH , P was OCH CH(CH ) and B was OCH CH(C H )). Nafion bound extensively to the two copolymers as shown by a variety of techniques. As well as quartz crystal microbalance with dissipation monitoring (QCM-D), the hybrid hydrogels were subjected to dynamic light scattering, rheology, and SAXS. Dr Antonios Kelarakis, senior researcher at the University of Central Lancashire, and lead investigator of the study explained their approach: "We didn't want to compromise the injectability of the polymers with the addition of Nafion, so once we knew the hybrid hydrogels had the strong mechanical properties we needed, we used SAXS to explore their structure." At I22, the hydrogel mixtures were mounted between mica windows in a liquid cell equipped with a water-bath for temperature control. Two-dimensional SAXS patterns were collected using a Pilatus P3-2M area detector and all patterns were corrected for the incident beam fluctuations as well as air and instrument scatter prior to conversion to one-dimensional profiles. The addition of Nafion was shown to enhance the viscoelasticity of the existing copolymers, thereby improving their mechanical strength. Moreover, the mixtures also underwent sharp and thermally reversible sol-gel transitions below body temperature, indicating that they retained their injectable capability. The systems were also tested for their ability to release ibuprofen, and Nafion was shown to drastically decrease the release of the drug; an effect believed to be conferred by a lower porosity or stronger matrix-drug interactions. Dr Kelarakis elaborated on these discoveries, "As well as a vehicle for medicines, this polymer complex could be used as a bio-ink for 3-D printing as it easily converts from a liquid to a gel. There are few materials currently available for this technique, but we have shown we can make a promising material that can withstand a lot of stress." The next step for this fascinating research is a full investigation into the evolution of the hydrogel complex during stress, which will be accomplished in situ using a rheometer on I22. The team aim to explore the effects of Nafion on other polymers and also intend to introduce nanoparticles to the hydrogels, so that they could be used for bioimaging. The hope is that imaging molecules could be slowly released to the body close to the site of interest (such as a wound) to illuminate selected physiological components. Explore further: Polymer puts new medical solutions within reach More information: D. Fernandes et al. Novel hydrogels containing Nafion and poly(ethylene oxide) based block copolymers, Polymer (2017). DOI: 10.1016/j.polymer.2017.02.094


News Article | April 19, 2017
Site: phys.org

Diatoms between 0.01 and 0.02 mm, consisting of a single cell surrounded by an artificially colored silica skeleton. The alga in green is present in clean environments, while the orange one lives in more polluted water. Credit: Laure Apothéloz-Perret-Gentil, UNIGE Diatoms are unicellular algae particularly sensitive to changes that affect their aquatic environment. This is why they are used as bioindicators for the biological monitoring of water quality. However, their microscopic identification in river samples requires a lot of time and skill. Biologists from the University of Geneva (UNIGE), Switzerland, have succeeded in establishing a water quality index based solely on the DNA sequences of the diatoms present in the samples, without needing to identify each species visually. This study, published in the journal Molecular Ecology Resources, presents a revolutionary tool to process a very large number of samples in parallel, allowing wide coverage of the monitored sites in a reduced time and at a lower cost. The degree of pollution of rivers resulting from human activities is assessed using different biotic indices. The latter reflect the ecological status of a river based on the quantity and diversity of organisms selected as bioindicators, due to their ecological preferences and tolerance to pollution. This is the case of diatoms, algae consisting of a single cell surrounded by a silica skeleton, recommended by the European Union and Switzerland as one of the ideal bioindicators for rivers and lakes. The quality of rivers is determined using the Swiss diatom index (DI-CH), whose value defines the ecological status. "The morphological identification of the different species present in each sample, however, no longer meets the needs of rapid and reliable bioassessment measures introduced to protect aquatic environments. This is why we have tried to develop a new method," says Jan Pawlowski, professor at the Department of Genetics and Evolution of the UNIGE Faculty of Science. In collaboration with the Geneva Water Ecology Service (SECOE) and the PhycoEco environmental office in La Chaux-de-Fonds, Switzerland, the researchers analyzed the 90 or so samples taken in different rivers in Switzerland and determined their ecological status using the DI-CH. They have thus established a reference system in order to validate the molecular index under development. The latter is based on the DNA sequences characteristic of all the diatom species which may be present in these samples. "The whole range of DNA sequences revealed in each sample corresponds to a specific DI-CH quality index. Furthermore, each sequence identified has a different distribution and is detected in variable amounts from one sample to another. By integrating all these data, we were able to calculate an ecological value for each sequence, without having to identify the species to which it belongs," explains Laure Apothéloz-Perret-Gentil, a member of the Geneva group and the first author of the study. This approach makes it possible to determine the quality of water using all of these ecological values. "Our assessment was correct for almost 80 percent of the samples, which is very encouraging. Increasing the number and diversity of samples will allow us to calibrate our method for future routine, large-scale analyses," indicates Jan Pawlowski. The synchronous processing of a large number of samples in record time and at a reduced cost is not the only advantage of this new tool. The molecular index developed by the biologists from UNIGE could easily be adapted to other groups of unicellular bioindicators: a major asset for monitoring various types of aquatic ecosystems. Explore further: Using genetics to measure the environmental impact of salmon farming More information: Laure Apothéloz-Perret-Gentil et al. Taxonomy-free molecular diatom index for high-throughput eDNA biomonitoring, Molecular Ecology Resources (2017). DOI: 10.1111/1755-0998.12668


SACRAMENTO, CA / ACCESSWIRE / April 28, 2017 / Taechyon Robotics Corporation has closed their seed round of $1 million by a strategic single principal investor, Shenzen O-film Tech Co Ltd (002456:CH). Taechyon Robotics' flagship product b08 the Robot is a social robot designed for home entertainment, companionship, and utility functions. Taechyon's key technology includes introducing interchangeable multiple interactive personalities in a single robot with conversational AI that is trained and customized via crowd-sourcing and gamification. "What separates our technology from other social robot competitors is that we leverage existing consumer channels, such as the iOS App Store, Google Play, Facebook, and Steam VR, to make a game out of training the AI with entertaining chat responses. In the beginning, our AI chat response system will start like others - rough and choppy; however, eventually the chat capabilities are going to become entertaining, creating hyper-engaging, witty, yet endearing robot personalities," said Steve Favis, CTO and Co-founder of Taechyon. Taechyon's technology will allow users to develop their own robot personalities, share them with other users, and even sell them in future robotic personality markets. Users can help shape the b08 personality type they really want for themselves, unlike other current systems in which individual users do not have the ability to customize their robots with their own content and responses as per their taste. There is a human catering or moderation element involved at the backend, which prevents the "trolling" of the developed AI personalities, similar to what happened to Microsoft's Tey Chatbot on Twitter. Taechyon has just released a silent launch of the first b08 training game on the iOS App Store for user acceptance testing and server stress testing. Their first iOS app is called "b08 the Robot with Watson." "We are using IBM Watson's Speech recognition and token voice from the IBM Jeopardy challenge for our first interactive multiple-personality Chatbot App combo. Some responses in our multiple personality Chatbot are answered by the talking comedic head b08, while the others by the more seriously trained computer Chatbot we call the 'Talking Tummy TV.' This will allow us to literally write endless comedic dialogues between these two personality elements or even more in a single robot. We will introduce and offer other known smart voice interaction systems such as Amazon's Alexa or Wolfram Alpha type personalities to our users, as well. If any smart voice interaction system is available commercially to us, we can launch and deliver it as a personality within b08, as well. Our robot will have home IoT, utility, security, video conferencing, and control features similar to other social home robots entering the market. In addition, our premium models will have premium computer hardware for gaming such as high-end Intel CPUs and NVIDIA's Pascal Graphics Cards. After all, if a Robot has a computer inside, we might as well allow users to play high-quality blockbuster video games on the robot and with robot personalities as well. There are more capabilities coming up, but we will release those as we make progress," said Steve as his face lit up in excitement. "We connected with O-film in October of 2016. We are very fortunate to have O-film recognize the potential in the scope of our technology and the ability of the team very early on. They decided to make a strategic investment in us for the whole amount of $1M allocated for the seed round. We are excited that as our strategic partner, they bring critical components and large-scale manufacturing experience to the table," said Dr. Deepak Srivastava, CEO and co-Founder of Taechyon. "The seed round investment will be mainly used for on-boarding the team, signing up early customers and developers through our iOS App, and exhibiting moving, talking, and entertaining b08 robot prototypes at various Silicon Valley locations during the summer and fall of 2017. We will start booking pre-orders during the fall of 2017, with early beta shipments scheduled for the summer of 2018. For the next round of funding, I am already looking for other global strategic partners from the AI chip hardware, consumer appliances and electronics, telecom, gaming, and digital media entertainment companies," added Dr. Srivastava. Shenzen O-film Tech Co Ltd (002456:CH) is a global tier-1 manufacturer of Cameras, Displays, and Sensors of various types www.o-film.com. Michael Yoo, Head of Innovation Center of O-film, USA said, "Taechyon Robotics has unique features and a great growth potential in the near future. Their home entertaining/social robots provide a great opportunity for integrating all state-of-the-art technologies in Cameras, Displays, and Sensors with AI and the related software in the exciting new markets." b08 the Robot is a Social Home Entertainment Robot designed for engaging chatbot AI. b08 stands 4' 2" tall and has many home utility feature capabilities.


VANCOUVER, BC--(Marketwired - April 26, 2017) - Strategic Metals Ltd. (TSX VENTURE: SMD) ("Strategic" or the "Company") is pleased to announce that the Plan of Arrangement (the "Arrangement") to spin-out certain of the Company's assets into Trifecta Gold Ltd. ("Trifecta") was approved by Strategic shareholders at its Special General Meeting held on April 21, 2017, with 99.71% of the votes cast at the Meeting having been in favour of the Arrangement. Under the Arrangement, Strategic will distribute to its own shareholders most of the Trifecta common shares it has acquired, on the basis of one Trifecta common share for each four and one-half (4 ½) shares of Strategic held. The Trifecta common shares will be distributed to persons who are shareholders of Strategic at the close of business (Vancouver time) on May 5, 2017 (the "Share Distribution Record Date"), with the distribution to be made contemporaneously with the listing of Trifecta's shares on the TSX Venture Exchange (the "Exchange"). Strategic obtained final approval for the Plan of Arrangement from the Supreme Court of British Columbia (the "Court") on April 25, 2017. The final Order of the Court will be filed in due course with the British Columbia Registrar of Companies, in conjunction with the listing of Trifecta's common shares on the Exchange. In that regard, documentation has been filed with the Exchange in support of that listing, with further details in respect of said listing to be disclosed by subsequent news release. Strategic shareholders will not be required to do anything to obtain their Trifecta common shares, as they will be distributed pursuant to the shareholders' list maintained by Strategic's registrar and transfer agent, Computershare Investor Services Inc., as of the Share Distribution Record Date. Trifecta After Completion Of The Arrangement Upon completion of the Arrangement, Trifecta will hold interests in four mineral properties, all located within the White Gold District of the Dawson Range Gold Belt in southwestern Yukon. The Eureka, Triple Crown (formerly known as the OOO) and Treble (formerly known as the LLL) properties are all 100% owned by Trifecta. The fourth property (the Trident property) consists of three claim blocks optioned from arm's-length optionors and a number of claims wholly-owned by Trifecta which it acquired by staking. Of the claims blocks under option, Trifecta has the optional rights to acquire a 100% interest in the CH claims and up to a 75% interest in the Squid East and Squid West claims. Full particulars of Trifecta's mineral property interests are disclosed in the Company's Notice of Meeting and Management Information Circular as distributed to its shareholders in connection with the Special General Meeting held on April 21, 2017, and as filed on SEDAR. Following the completion of the Arrangement, Trifecta will be a reporting issuer in British Columbia and Alberta, the common shares of which will be listed on the Exchange. As of the listing of Trifecta's shares on the Exchange, Strategic shareholders will hold approximately 86% of the issued and outstanding Trifecta shares, with approximately 9.2% of those shares to be held by Strategic and approximately 4.8% of those shares to be held by the property optionors referred to above. Completion of the Arrangement is subject to a number of conditions, including, but not limited to, Exchange acceptance for both the Arrangement and the listing of Trifecta's common shares thereon. The Arrangement and the listing of Trifecta's common shares on the Exchange will not be effected until all such conditions have been satisfied. Strategic Metals After Completion Of The Arrangement Following the completion of the Arrangement, Strategic will remain a project generator and the largest claimholder in the Yukon. Strategic's portfolio of more than 100 projects is the result of 50 years of focussed exploration and research by a team with a track record of major discoveries. Current projects available for option, joint venture or sale include drill-confirmed prospects and drill-ready targets with high-grade surface showings, geochemical anomalies and geophysical features similar to those at nearby deposits. Strategic has a current cash position of over $16 million and significant shareholdings in a number of active mineral exploration companies including 45.2% of Rockhaven Resources Ltd., 8.3% of ATAC Resources Ltd., 31.1% of Precipitate Gold Corp. and 14.3% of Silver Range Resources Ltd. ON BEHALF OF THE BOARD For further information concerning Strategic or its various exploration projects please visit our website at www.strategicmetalsltd.com. This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities of the Company in the United States. The Company's securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. Completion of the Arrangement is subject to a number of conditions, including, but not limited to, Exchange acceptance for both the Arrangement and the listing of Trifecta's common shares thereon. The Arrangement and the listing of Trifecta's common shares on the Exchange will not be effected until all such conditions have been satisfied. Investors are cautioned that, except as disclosed in Strategic's Management Information Circular, any information released or received with respect to the Arrangement may not be accurate or complete and should not be relied upon. This news release may contain forward looking statements based on assumptions and judgments of management regarding future events or results that may prove to be inaccurate as a result of exploration and other risk factors beyond its control, and actual results may differ materially from the expected results. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


News Article | April 27, 2017
Site: globenewswire.com

ALLSCHWIL, SWITZERLAND - 27 April 2017 - Actelion Ltd (SIX: ATLN) today announced that Janssen Holding GmbH, a Swiss subsidiary of Johnson & Johnson, published the definitive notice of the end result of its all-cash public tender offer in Switzerland to acquire all publicly held shares of Actelion Ltd for $280 per share, payable in US dollars, per the offer prospectus of February 16, 2017. At the expiration of the additional acceptance period on April 21, 2017, 16:00 hrs CEST, a total of 99,303,760 Actelion shares were tendered, corresponding to 92.51% of the 107,339,642 Actelion shares covered by the tender offer. Including the Actelion shares tendered, Janssen and Actelion, a person acting in concert with Janssen, held as of the end of the additional acceptance period 100,665,760 Actelion shares, corresponding to 92.62% of the voting rights and the share capital of Actelion (including the Actelion shares issued until the end of the additional acceptance period out of Actelion's conditional capital due to the exercise of awards under Actelion's equity plans). According to SIX Swiss Exchange's media release of April 24, 2017, Actelion will be excluded from the SMI® blue-chip index with effect from May 3, 2017. Based on the current understanding of the regulatory approval proceedings in different jurisdictions, the settlement of the tender offer is expected to occur, subject to the satisfaction of all relevant conditions to the tender offer, including regulatory approvals, towards the end of the second quarter of 2017. As previously announced, as part of the transaction, Actelion will spin out its drug discovery operations and early-stage clinical development assets into a newly created Swiss biopharmaceutical company, Idorsia Ltd. The shares of Idorsia are expected to be distributed to Actelion's shareholders as a dividend in kind and listed on the SIX Swiss Exchange on the day of the settlement of the tender offer. An affiliate of Janssen Holding GmbH will initially hold 16 percent of the shares of Idorsia Ltd and have rights to potentially increase to 32 percent through a convertible note. ABOUT ACTELION LTD Actelion Ltd. is a leading biopharmaceutical company focused on the discovery, development and commercialization of innovative drugs for diseases with significant unmet medical need. Actelion is a leader in the field of pulmonary arterial hypertension (PAH). Our portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications. Although not available in all countries, Actelion has treatments approved by health authorities for a number of specialist diseases including Type 1 Gaucher disease, Niemann-Pick type C disease, Digital Ulcers in patients suffering from systemic sclerosis, and mycosis fungoides type cutaneous T-cell lymphoma. Founded in late 1997, with now over 2,500 dedicated professionals covering all key markets around the world including Europe, the US, Japan, China, Russia and Mexico, Actelion has its corporate headquarters in Allschwil / Basel, Switzerland. Actelion shares are currently traded on the SIX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMI®). All trademarks are legally protected. For further information please contact:  Andrew C. Weiss Senior Vice President, Head of Investor Relations & Corporate Communications Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil +41 61 565 62 62 www.actelion.com NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding the potential transaction between Johnson & Johnson and Actelion Ltd. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson and Actelion. Risks and uncertainties include, but are not limited to: the satisfaction of closing conditions for the transaction, including clearance by relevant merger control authorities and the receipt of regulatory approvals for the transaction; the possibility that the transaction will not be completed in the expected timeframe or at all; the potential that the expected benefits and opportunities of the transaction, if completed, may not be realized or may take longer to realize than expected; challenges inherent in  product research and development, including the uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; economic conditions, including currency exchange and interest rate fluctuations; competition, including technological advances, new products and patents attained by competitors; changes to applicable laws and regulations, including tax laws and domestic and foreign health care reforms; adverse litigation or government action; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; and trends toward health care cost containment. In addition, if and when the transaction is consummated, there will be risks and uncertainties related to the ability of the Johnson & Johnson family of companies to successfully integrate the products, employees/operations and clinical work of Actelion, as well as the ability to ensure continued performance or market growth of Actelion's products. A further list and description of these risks, uncertainties and other factors and the general risks associated with the respective businesses of Johnson & Johnson and Actelion can be found in Johnson & Johnson's publicly available filings with the U.S. Securities and Exchange Commission, and Actelion's publicly available filings on its website. Copies of these filings, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com, www.actelion.com or on request from Johnson & Johnson or Actelion. Neither Johnson & Johnson nor Actelion undertakes to update any forward-looking statement as a result of new information or future events or developments. IMPORTANT ADDITIONAL INFORMATION This release is for informational purposes only and does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer, to purchase or subscribe for any registered shares in Actelion or Actelion's ADSs, nor shall it form the basis of, or be relied on in connection with, any contract there for.  Shareholders of Actelion are urged to read the offer documents which are or will be available at http://www.investor.jnj.com/publictenderoffer.cfm. OFFER RESTRICTIONS The public tender (öffentliches Kaufangebot) offer described in the offer prospectus (the Offer) is not being made and will not be made, directly or indirectly, in any country or jurisdiction in which such an Offer would be considered unlawful or otherwise violate any applicable laws or regulations, or which would require Johnson & Johnson or any of its direct or indirect subsidiaries to change or amend the terms or conditions of the Offer in any material way, to make an additional filing with any governmental, regulatory or other authority or take additional action in relation to the Offer. It is not intended to extend the Offer to any such country or jurisdiction. Any such documents relating to the Offer must neither be distributed in any such country or jurisdiction nor be sent into such country or jurisdiction, and must not be used for the purpose of soliciting the purchase of securities of Actelion by any person or entity resident or incorporated in any such country or jurisdiction. NOTICE TO U.S. HOLDERS The Offer described in this communication is being made for the registered shares of Actelion, a Swiss corporation (Aktiengesellschaft) whose shares are listed on the SIX Swiss Exchange (SIX), and is subject to Swiss disclosure and procedural requirements, which are different from those of the United States of America (U.S.). The Offer is being made in the U.S. pursuant to Section 14(e) of, and Regulation 14E under, the U.S. Securities Exchange Act of 1934, as amended (the U.S. Exchange Act), subject to the exemptions provided by Rule 14d-1 and Rule 14e-5 under the U.S. Exchange Act and any exemptions from such requirements granted by the U.S. Securities and Exchange Commission (the SEC), and otherwise in accordance with the requirements of Swiss law. Accordingly, the Offer is subject to disclosure and other procedural requirements, including with respect to withdrawal rights, settlement procedures and timing of payments that are different from those applicable under U.S. domestic tender offer procedures and laws. U.S. holders of registered shares of Actelion (Actelion Shares) are encouraged to consult with their legal, financial and tax advisors regarding the Offer. The shareholders of Actelion should review the offer prospectus (the Offer Prospectus) and all other Offer documents carefully. According to the laws of Switzerland, Actelion Shares tendered into the Offer may generally not be withdrawn after they are tendered except under certain circumstances, in particular if a competing offer for the Actelion Shares is launched. In accordance with the laws of Switzerland and subject to applicable regulatory requirements, Johnson & Johnson and its subsidiaries and affiliates or their respective nominees or brokers (acting as agents for Johnson & Johnson, its subsidiaries or affiliates) may from time to time after the date of the Offer Prospectus, and other than pursuant to the Offer, directly or indirectly, purchase or arrange to purchase Actelion Shares or any securities that are convertible into, exchangeable for or exercisable for Actelion Shares from shareholders of Actelion who are willing to sell their Actelion Shares outside the Offer from time to time, including purchases in the open market at prevailing prices or in private transactions at negotiated prices, and shall comply with applicable laws and regulations in Switzerland and applicable U.S. securities regulation and pursuant to exemptive relief granted by the SEC from Rule 14e-5 under the U.S. Exchange Act. Any such purchases will not be made at prices higher than the offer price or on terms more favorable than those offered pursuant to the Offer unless the offer price is increased accordingly. Any information about such purchases or arrangements to purchase will be publicly disclosed in the U.S. on Johnson & Johnson's website to the extent that such information is made public in accordance with the applicable laws and regulations of Switzerland. In addition, the financial advisor to Actelion and, subject to applicable Swiss and U.S. regulation and pursuant to exemptive relief granted by the SEC from Rule 14e-5 under the U.S. Exchange Act, the financial advisor to Johnson & Johnson and its affiliates may also engage in ordinary course trading activities in securities of Actelion, which may include purchases or arrangements to purchase such securities. It may be difficult for U.S. holders to enforce their rights and any claim arising out of U.S. securities laws, since the Offeror and Actelion are located in a non-U.S. jurisdiction, and some or all of their officers and directors may be residents of a non-U.S. jurisdiction. U.S. holders may not be able to sue a non-U.S. company or its officers or directors in a U.S. or non-U.S. court for violations of the U.S. securities laws. Further, it may be difficult to compel a non-U.S. company and its affiliates to subject themselves to a U.S. court's judgment. The receipt of cash pursuant to the Offer by a U.S. holder of Actelion Shares may be a taxable transaction for U.S. federal income tax purposes and under applicable U.S. state and local laws, as well as foreign and other tax laws. In addition, the receipt of shares of Idorsia Ltd pursuant to the demerger distribution by a U.S. holder of Actelion Shares may be taxable as a dividend for U.S. federal income tax purposes and under applicable U.S. state and local laws, as well as foreign and other tax laws. Each shareholder of Actelion is urged to consult his or her independent professional advisor immediately regarding the tax consequences of an acceptance of the Offer. Neither the SEC nor any securities commission of any State of the U.S. has (a) approved or disapproved of the Offer, (b) passed upon the merits or fairness of the Offer, or (c) passed upon the adequacy or accuracy of the disclosure in the Offer Prospectus. Any representation to the contrary is a criminal offence in the U.S. AMERICAN DEPOSITARY SHARES AND AMERICAN DEPOSITARY RECEIPTS Johnson & Johnson, its subsidiaries and affiliates are aware that there are "unsponsored" American Depositary Receipt Programs concerning Actelion Shares. The Offer is not being made for American Depositary Shares representing Actelion Shares (ADSs), nor for American Depositary Receipts evidencing such ADSs (ADRs). However, the Offer is being made for the Actelion Shares that are represented by the ADSs. Holders of ADSs and ADRs are encouraged to consult with the appropriate depositary regarding the tender of Actelion Shares that are represented by ADSs. Johnson & Johnson, its subsidiaries and affiliates are unaware of whether any respective depositary will make arrangements to tender the underlying Actelion Shares into the Offer on behalf of holders of ADSs or ADRs. Holders of ADSs may present their ADSs to the appropriate depositary for cancellation and (upon compliance with the terms of the deposit agreements relating to the "unsponsored" American Depositary Receipt Program concerning Actelion Shares, including payment of the depositary's fees and any applicable transfer fees, taxes and governmental charges) delivery of Actelion Shares to them, in order to become shareholders of Actelion. The Offer may then be accepted in accordance with its terms for the Actelion Shares delivered to holders of ADSs upon such cancellation. Holders of ADSs should be aware, however, that in order to tender in this manner, they may need to have an account in Switzerland into which the Actelion Shares can be delivered.


News Article | April 24, 2017
Site: globenewswire.com

ALLSCHWIL, SWITZERLAND - 24 April 2017 - Actelion Ltd (SIX: ATLN) today announced that Janssen Holding GmbH, a Swiss subsidiary of Johnson & Johnson, published the provisional notice of the end result of its all-cash public tender offer in Switzerland to acquire all publicly held shares of Actelion Ltd for $280 per share, payable in US dollars, per the offer prospectus of February 16, 2017. At the expiration of the additional acceptance period on April 21, 2017, 16:00 hrs CEST, a total of 99,303,760 Actelion shares were tendered, corresponding to 92.51% of the 107,339,642 Actelion shares covered by the tender offer. Including the Actelion shares tendered, Janssen and Actelion, a person acting in concert with Janssen, held as of the end of the additional acceptance period 100,665,760 Actelion shares, corresponding to 92.62% of the voting rights and the share capital of Actelion (including the Actelion shares issued until the end of the additional acceptance period out of Actelion's conditional capital due to the exercise of awards under Actelion's equity plans). As a consequence of this tender rate, Actelion expects to be excluded from the SMI® blue-chip index by SIX Swiss Exchange. Based on the current understanding of the regulatory approval proceedings in different jurisdictions, the settlement of the tender offer is expected to occur, subject to the satisfaction of all relevant conditions to the tender offer, including regulatory approvals, towards the end of the second quarter of 2017. As previously announced, as part of the transaction, Actelion will spin out its drug discovery operations and early-stage clinical development assets into a newly created Swiss biopharmaceutical company, Idorsia Ltd. The shares of Idorsia are expected to be distributed to Actelion's shareholders as a dividend in kind and listed on the SIX Swiss Exchange on the day of the settlement of the tender offer. An affiliate of Janssen Holding GmbH will initially hold 16 percent of the shares of Idorsia Ltd and have rights to potentially increase to 32 percent through a convertible note. ABOUT ACTELION LTD Actelion Ltd. is a leading biopharmaceutical company focused on the discovery, development and commercialization of innovative drugs for diseases with significant unmet medical need. Actelion is a leader in the field of pulmonary arterial hypertension (PAH). Our portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications. Although not available in all countries, Actelion has treatments approved by health authorities for a number of specialist diseases including Type 1 Gaucher disease, Niemann-Pick type C disease, Digital Ulcers in patients suffering from systemic sclerosis, and mycosis fungoides type cutaneous T-cell lymphoma. Founded in late 1997, with now over 2,500 dedicated professionals covering all key markets around the world including Europe, the US, Japan, China, Russia and Mexico, Actelion has its corporate headquarters in Allschwil / Basel, Switzerland. Actelion shares are currently traded on the SIX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMI®). All trademarks are legally protected. For further information please contact:  Andrew C. Weiss Senior Vice President, Head of Investor Relations & Corporate Communications Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil +41 61 565 62 62 www.actelion.com NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding the potential transaction between Johnson & Johnson and Actelion Ltd. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson and Actelion. Risks and uncertainties include, but are not limited to: the satisfaction of closing conditions for the transaction, including clearance by relevant merger control authorities and the receipt of regulatory approvals for the transaction; the possibility that the transaction will not be completed in the expected timeframe or at all; the potential that the expected benefits and opportunities of the transaction, if completed, may not be realized or may take longer to realize than expected; challenges inherent in  product research and development, including the uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; economic conditions, including currency exchange and interest rate fluctuations; competition, including technological advances, new products and patents attained by competitors; changes to applicable laws and regulations, including tax laws and domestic and foreign health care reforms; adverse litigation or government action; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; and trends toward health care cost containment. In addition, if and when the transaction is consummated, there will be risks and uncertainties related to the ability of the Johnson & Johnson family of companies to successfully integrate the products, employees/operations and clinical work of Actelion, as well as the ability to ensure continued performance or market growth of Actelion's products. A further list and description of these risks, uncertainties and other factors and the general risks associated with the respective businesses of Johnson & Johnson and Actelion can be found in Johnson & Johnson's publicly available filings with the U.S. Securities and Exchange Commission, and Actelion's publicly available filings on its website. Copies of these filings, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com, www.actelion.com or on request from Johnson & Johnson or Actelion. Neither Johnson & Johnson nor Actelion undertakes to update any forward-looking statement as a result of new information or future events or developments. IMPORTANT ADDITIONAL INFORMATION This release is for informational purposes only and does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer, to purchase or subscribe for any registered shares in Actelion or Actelion's ADSs, nor shall it form the basis of, or be relied on in connection with, any contract there for.  Shareholders of Actelion are urged to read the offer documents which are or will be available at http://www.investor.jnj.com/publictenderoffer.cfm. OFFER RESTRICTIONS The public tender (öffentliches Kaufangebot) offer described in the offer prospectus (the Offer) is not being made and will not be made, directly or indirectly, in any country or jurisdiction in which such an Offer would be considered unlawful or otherwise violate any applicable laws or regulations, or which would require Johnson & Johnson or any of its direct or indirect subsidiaries to change or amend the terms or conditions of the Offer in any material way, to make an additional filing with any governmental, regulatory or other authority or take additional action in relation to the Offer. It is not intended to extend the Offer to any such country or jurisdiction. Any such documents relating to the Offer must neither be distributed in any such country or jurisdiction nor be sent into such country or jurisdiction, and must not be used for the purpose of soliciting the purchase of securities of Actelion by any person or entity resident or incorporated in any such country or jurisdiction. NOTICE TO U.S. HOLDERS The Offer described in this communication is being made for the registered shares of Actelion, a Swiss corporation (Aktiengesellschaft) whose shares are listed on the SIX Swiss Exchange (SIX), and is subject to Swiss disclosure and procedural requirements, which are different from those of the United States of America (U.S.). The Offer is being made in the U.S. pursuant to Section 14(e) of, and Regulation 14E under, the U.S. Securities Exchange Act of 1934, as amended (the U.S. Exchange Act), subject to the exemptions provided by Rule 14d-1 and Rule 14e-5 under the U.S. Exchange Act and any exemptions from such requirements granted by the U.S. Securities and Exchange Commission (the SEC), and otherwise in accordance with the requirements of Swiss law. Accordingly, the Offer is subject to disclosure and other procedural requirements, including with respect to withdrawal rights, settlement procedures and timing of payments that are different from those applicable under U.S. domestic tender offer procedures and laws. U.S. holders of registered shares of Actelion (Actelion Shares) are encouraged to consult with their legal, financial and tax advisors regarding the Offer. The shareholders of Actelion should review the offer prospectus (the Offer Prospectus) and all other Offer documents carefully. According to the laws of Switzerland, Actelion Shares tendered into the Offer may generally not be withdrawn after they are tendered except under certain circumstances, in particular if a competing offer for the Actelion Shares is launched. In accordance with the laws of Switzerland and subject to applicable regulatory requirements, Johnson & Johnson and its subsidiaries and affiliates or their respective nominees or brokers (acting as agents for Johnson & Johnson, its subsidiaries or affiliates) may from time to time after the date of the Offer Prospectus, and other than pursuant to the Offer, directly or indirectly, purchase or arrange to purchase Actelion Shares or any securities that are convertible into, exchangeable for or exercisable for Actelion Shares from shareholders of Actelion who are willing to sell their Actelion Shares outside the Offer from time to time, including purchases in the open market at prevailing prices or in private transactions at negotiated prices, and shall comply with applicable laws and regulations in Switzerland and applicable U.S. securities regulation and pursuant to exemptive relief granted by the SEC from Rule 14e-5 under the U.S. Exchange Act. Any such purchases will not be made at prices higher than the offer price or on terms more favorable than those offered pursuant to the Offer unless the offer price is increased accordingly. Any information about such purchases or arrangements to purchase will be publicly disclosed in the U.S. on Johnson & Johnson's website to the extent that such information is made public in accordance with the applicable laws and regulations of Switzerland. In addition, the financial advisor to Actelion and, subject to applicable Swiss and U.S. regulation and pursuant to exemptive relief granted by the SEC from Rule 14e-5 under the U.S. Exchange Act, the financial advisor to Johnson & Johnson and its affiliates may also engage in ordinary course trading activities in securities of Actelion, which may include purchases or arrangements to purchase such securities. It may be difficult for U.S. holders to enforce their rights and any claim arising out of U.S. securities laws, since the Offeror and Actelion are located in a non-U.S. jurisdiction, and some or all of their officers and directors may be residents of a non-U.S. jurisdiction. U.S. holders may not be able to sue a non-U.S. company or its officers or directors in a U.S. or non-U.S. court for violations of the U.S. securities laws. Further, it may be difficult to compel a non-U.S. company and its affiliates to subject themselves to a U.S. court's judgment. The receipt of cash pursuant to the Offer by a U.S. holder of Actelion Shares may be a taxable transaction for U.S. federal income tax purposes and under applicable U.S. state and local laws, as well as foreign and other tax laws. In addition, the receipt of shares of Idorsia Ltd pursuant to the demerger distribution by a U.S. holder of Actelion Shares may be taxable as a dividend for U.S. federal income tax purposes and under applicable U.S. state and local laws, as well as foreign and other tax laws. Each shareholder of Actelion is urged to consult his or her independent professional advisor immediately regarding the tax consequences of an acceptance of the Offer. Neither the SEC nor any securities commission of any State of the U.S. has (a) approved or disapproved of the Offer, (b) passed upon the merits or fairness of the Offer, or (c) passed upon the adequacy or accuracy of the disclosure in the Offer Prospectus. Any representation to the contrary is a criminal offence in the U.S. AMERICAN DEPOSITARY SHARES AND AMERICAN DEPOSITARY RECEIPTS Johnson & Johnson, its subsidiaries and affiliates are aware that there are "unsponsored" American Depositary Receipt Programs concerning Actelion Shares. The Offer is not being made for American Depositary Shares representing Actelion Shares (ADSs), nor for American Depositary Receipts evidencing such ADSs (ADRs). However, the Offer is being made for the Actelion Shares that are represented by the ADSs. Holders of ADSs and ADRs are encouraged to consult with the appropriate depositary regarding the tender of Actelion Shares that are represented by ADSs. Johnson & Johnson, its subsidiaries and affiliates are unaware of whether any respective depositary will make arrangements to tender the underlying Actelion Shares into the Offer on behalf of holders of ADSs or ADRs. Holders of ADSs may present their ADSs to the appropriate depositary for cancellation and (upon compliance with the terms of the deposit agreements relating to the "unsponsored" American Depositary Receipt Program concerning Actelion Shares, including payment of the depositary's fees and any applicable transfer fees, taxes and governmental charges) delivery of Actelion Shares to them, in order to become shareholders of Actelion. The Offer may then be accepted in accordance with its terms for the Actelion Shares delivered to holders of ADSs upon such cancellation. Holders of ADSs should be aware, however, that in order to tender in this manner, they may need to have an account in Switzerland into which the Actelion Shares can be delivered.

Loading CH collaborators
Loading CH collaborators